https://azd4573inhibitor.com/n....ationwide-commence-u
Here, we exploit structural differences in the man and schistosome BCL-2 (sBCL-2) pro-survival proteins toward a novel therapy technique for schistosomiasis. The benzothiazole hydrazone scaffold previously used to target person BCL-XL ended up being repurposed as a starting point to target sBCL-2. We applied X-ray structural data to inform optimization after which applied a scaffold-hop strategy to identify the 5-carboxamide thiazole hydrazone scaffold (43) with powerful sBCL-2 activity (IC50 3
Like
Comment
Share
